WO2007115620A3 - Neuartige cyclobutyl-verbindungen als kinase-inhibitoren - Google Patents

Neuartige cyclobutyl-verbindungen als kinase-inhibitoren Download PDF

Info

Publication number
WO2007115620A3
WO2007115620A3 PCT/EP2007/001993 EP2007001993W WO2007115620A3 WO 2007115620 A3 WO2007115620 A3 WO 2007115620A3 EP 2007001993 W EP2007001993 W EP 2007001993W WO 2007115620 A3 WO2007115620 A3 WO 2007115620A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel
kinase inhibitors
compounds
cyclobutyl compounds
cyclobutyl
Prior art date
Application number
PCT/EP2007/001993
Other languages
English (en)
French (fr)
Other versions
WO2007115620A2 (de
Inventor
Timo Heinrich
Wolfgang Staehle
Hartmut Greiner
Andree Blaukat
Original Assignee
Merck Patent Gmbh
Timo Heinrich
Wolfgang Staehle
Hartmut Greiner
Andree Blaukat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Timo Heinrich, Wolfgang Staehle, Hartmut Greiner, Andree Blaukat filed Critical Merck Patent Gmbh
Priority to AU2007236361A priority Critical patent/AU2007236361A1/en
Priority to CA002647690A priority patent/CA2647690A1/en
Priority to JP2009503443A priority patent/JP2009535300A/ja
Priority to US12/296,138 priority patent/US20100160356A1/en
Priority to EP07711852A priority patent/EP2004651A2/de
Publication of WO2007115620A2 publication Critical patent/WO2007115620A2/de
Publication of WO2007115620A3 publication Critical patent/WO2007115620A3/de
Priority to IL194356A priority patent/IL194356A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Die Erfindung betrifft Verbindungen der Formel I, deren Herstellung und Verwendung zur Herstellung eines Medikaments zur Behandlung von Krankheiten, insbesondere Tumoren und/oder Krankheiten, an deren Entstehung oder Verlauf Protein-Kinasen beteiligt sind.
PCT/EP2007/001993 2006-04-07 2007-03-08 Neuartige cyclobutyl-verbindungen als kinase-inhibitoren WO2007115620A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2007236361A AU2007236361A1 (en) 2006-04-07 2007-03-08 Novel cyclobutyl compounds as kinase inhibitors
CA002647690A CA2647690A1 (en) 2006-04-07 2007-03-08 Novel cyclobutyl compounds as kinase inhibitors
JP2009503443A JP2009535300A (ja) 2006-04-07 2007-03-08 キナーゼ阻害剤としての新規なシクロブチル化合物
US12/296,138 US20100160356A1 (en) 2006-04-07 2007-03-08 Novel cyclobutyl compounds as kinase inhibitors
EP07711852A EP2004651A2 (de) 2006-04-07 2007-03-08 Neuartige cyclobutyl-verbindungen als kinase-inhibitoren
IL194356A IL194356A0 (en) 2006-04-07 2008-09-25 Novel cyclobutyl compounds as kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006016426A DE102006016426A1 (de) 2006-04-07 2006-04-07 Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
DE102006016426.1 2006-04-07

Publications (2)

Publication Number Publication Date
WO2007115620A2 WO2007115620A2 (de) 2007-10-18
WO2007115620A3 true WO2007115620A3 (de) 2007-11-29

Family

ID=38476568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/001993 WO2007115620A2 (de) 2006-04-07 2007-03-08 Neuartige cyclobutyl-verbindungen als kinase-inhibitoren

Country Status (8)

Country Link
US (1) US20100160356A1 (de)
EP (1) EP2004651A2 (de)
JP (1) JP2009535300A (de)
AU (1) AU2007236361A1 (de)
CA (1) CA2647690A1 (de)
DE (1) DE102006016426A1 (de)
IL (1) IL194356A0 (de)
WO (1) WO2007115620A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2385053B1 (de) 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Zwischenprodukte für die Herstellung von kondensierten bicyclischen mTOR-Inhibitoren
EP1981890A2 (de) 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNGESÄTTIGTE mTOR-HEMMER
KR20110017845A (ko) 2008-03-19 2011-02-22 오에스아이 파마슈티컬스, 인코포레이티드 Ｍｔｏｒ 억제자 염 형태
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
JOP20190230A1 (ar) * 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN103476776B (zh) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN102093364B (zh) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
EP2684007B1 (de) * 2011-03-09 2016-03-09 Hysitron, Inc. Dreidimensionaler wandler
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
MX2015016344A (es) 2013-05-27 2016-03-01 Novartis Ag Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
PL3004112T3 (pl) 2013-05-28 2018-02-28 Novartis Ag Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EP3071571A1 (de) 2013-11-21 2016-09-28 Novartis AG Pyrrolopyrrolonderivate und deren verwendung als bet-inhibitoren
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
JP6959924B2 (ja) 2015-09-23 2021-11-05 エアーピオ ファーマシューティカルズ， インコーポレイテッド Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法
CN107827893B (zh) * 2017-11-10 2020-03-27 常州齐晖药业有限公司 一种4-氯-7H-吡咯并[2,3-d]嘧啶的制备方法
CN115916966A (zh) * 2020-01-30 2023-04-04 加利福尼亚大学董事会 Strad结合剂及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028161A1 (en) * 1996-02-01 1997-08-07 Novartis Ag Novel pyrrolo[2,3-d]pyrimidines and their use as tyrosine kinase inhibitors
WO2002092599A1 (en) * 2001-05-14 2002-11-21 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509576A (pt) * 2004-04-02 2007-05-29 Osi Pharm Inc composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica
JP2009520028A (ja) * 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｉｇｆｒ抑制剤および抗癌剤の併用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028161A1 (en) * 1996-02-01 1997-08-07 Novartis Ag Novel pyrrolo[2,3-d]pyrimidines and their use as tyrosine kinase inhibitors
WO2002092599A1 (en) * 2001-05-14 2002-11-21 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives

Also Published As

Publication number Publication date
WO2007115620A2 (de) 2007-10-18
AU2007236361A1 (en) 2007-10-18
US20100160356A1 (en) 2010-06-24
JP2009535300A (ja) 2009-10-01
IL194356A0 (en) 2009-08-03
EP2004651A2 (de) 2008-12-24
CA2647690A1 (en) 2007-10-18
DE102006016426A1 (de) 2007-10-11

Similar Documents

Publication Publication Date Title
WO2007115620A3 (de) Neuartige cyclobutyl-verbindungen als kinase-inhibitoren
WO2008006547A3 (en) Pyrrolopyrimidines for pharmaceutical compositions
WO2008033562A3 (en) Kinase inhibitor compounds
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
WO2007095188A3 (en) Dihydrodiazepines useful as inhibitors of protein kinases
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2007087283A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
UA101611C2 (ru) СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2008137619A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
HK1135103A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
WO2008147626A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
WO2010042925A3 (en) Compositions and methods for treating alcohol use disorders, pain and other diseases
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2007139816A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07711852

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007711852

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 194356

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2647690

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12296138

Country of ref document: US

Ref document number: 2009503443

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007236361

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007236361

Country of ref document: AU

Date of ref document: 20070308

Kind code of ref document: A